SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               ------------------

                                    FORM 6-K

                        REPORT OF FOREIGN PRIVATE ISSUER

                    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                               Date: May 29, 2001

                             World Heart Corporation
               ---------------------------------------------------
               (Exact name of registrant as specified in charter)

                                      N/A
                                      ---
                 (Translation of registrant's name into English)

                                    Ontario
                                    -------
                         (Jurisdiction of organization)

                     1 Laser Street, Ottawa, Ontario K2E 7V1
                     ---------------------------------------
                    (Address of principal executive offices)

           Registrant's telephone number, international: (613)226-4278

          Indicate  by check  mark  whether  the  registrant  files or will file
annual reports under cover Form 20-F or Form 40-F.


                            Form 20-F X    Form 40-F    __


          Indicate  by check mark  whether  the  registrant  by  furnishing  the
information contained in this Form is also thereby furnishing the information to
the Commission  pursuant to Rule 12g3-2(b) under the Securities  Exchange Act of
1934.

                               Yes  __     No   X


          If "Yes" is marked,  indicate  below the file  number  assigned to the
registrant in connection with Rule 12g3-2(b):82-________.

<PAGE>

MESSAGE TO SHAREHOLDERS

World Heart  Corporation  (WorldHeart)  began 2001 in a much  stronger  position
compared to a year ago. The  acquisition  of Edwards  Novacor LLC  (Novacor) and
strategic  alliance with Edwards  Lifesciences LLC (Edwards),  completed on June
30, 2000,  dramatically  accelerated  the  development of  WorldHeart.  With the
integration completed by year-end, WorldHeart has the capability to increase the
rate of adoption of Novacor(R) LVAS,  speed the introduction of HeartSaver,  and
shorten the time to  profitability.  Novacor(R)  LVAS is approved  for sale as a
bridge to transplant in the United States and Canada, and is in a clinical trial
in the US for an alternative to medical  therapy  indication.  In Europe,  it is
approved  for use by  end-stage  heart  failure  patients  and is not limited to
bridge  applications.  To date,  there  have been more  than  1,200  recipients.
Subject to applicable  regulatory  approvals,  we expect its niche to be for use
with patients requiring life-long support or several months or years of support,
prior to potential recovery or transplantation. HeartSaver is expected to appeal
to a broader  share of  late-stage  heart  failure  patients to provide  support
throughout their lives.

WorldHeart is well positioned for the future:

  o  Focused on pulsatile ventricular assist;

  o  A reliable product in the market with more than 1,200 implants;

  o  A breakthrough product scheduled for clinical trials this year;

  o  One of the largest and most experienced teams in the heart assist industry;

  o  State-of-the-art facilities in Oakland, California and Ottawa, Ontario; and

  o  Total  assets  of $105.5  million  including  cash,  cash  equivalents  and
     short-term  investments of $37.0  million,  up from $37.7 million of assets
     and $35.8 million in cash, cash  equivalents and short-term  investments at
     the end of March 31, 2000.

These internal strengths, combined with clinical relationships in North America,
Europe and other countries,  and the strategic alliance with Edwards,  provide a
sound base for  success.  Absorption  of these  capacities  required  HeartSaver
clinical trials to be rescheduled for late 2001, with the product  incorporating
materials  used in Novacor(R)  LVAS and benefiting  from technical  enhancements
drawn in part from the experience of the Novacor team. We are confident that the
clinical experience and relationships arising from Novacor(R) LVAS implants, and
the  sales  and  distribution  capacity  through  the  Edwards  alliance,   will
contribute to the commercial  introduction of HeartSaver resulting in an overall
shortening  of the time to market and an  increase  in the rate of  adoption  of
HeartSaver.

The first quarter of 2001 began with significant  milestones for both Novacor(R)
LVAS and  HeartSaver  products.  In Italy,  a 36 year old man  received  a heart
transplant  after living for more than four years with his heart  supported by a
Novacor(R) LVAS. While living with the support of the device, he had returned to
his business of operating a restaurant  and to life with his young family.  This
experience  is the  longest of a growing  number of  patients  (now 88) who have
lived more than one year on their original Novacor(R) LVAS.

In Ottawa, the quarter began with the commencement of HeartSaver  production for
pre-clinical trials. After the Novacor acquisition in June 2000,  HeartSaver was
modified to benefit from use of the proprietary  polymer produced by Novacor and
to incorporate  technical  enhancements.  During the first quarter, the enhanced
HeartSaver was manufactured and in vivo pre-clinical  trials began. Five centers
in the United  States  and Canada  have  agreed to conduct in vivo  trials,  and
implants were initiated at two of these in March. The in vivo and in vitro trial
program will continue throughout the year,  producing data to support submission
to Health Canada for approval to begin  clinical  trials later this year, and to
support  application for clinical trials in Europe,  the United States and other
countries next year.

In the quarter,  the  Corporation  reported  gross  revenues from  operations of
$2,135,040  and net revenues of $602,657  after  deducting the estimated  charge
against gross  revenues for the full year arising from the Edwards  Lifesciences
LLC distribution  agreement.  There were no revenues from operations  during the
first quarter last year. Research and development  expenses for the quarter were
$6,850,992,  compared with $3,120,700 for the same period last year.  Total cash
applied to operations during the period was $8,553,324  compared with $4,431,077
for the same period last year. The net loss for the quarter was $12,911,804,  or
$0.85 per share, compared with a net loss of $4,558,885,  or $0.32 per share for
the same period in the  previous  year.  Cash and  near-cash  resources  totaled
$37,047,414 at March 31, 2001,  compared with  $35,825,453 at the same date last
year and  $46,547,542  at December 31, 2000.  Application of cash in the quarter
included  a  non-recurring   payment  of  $1,215,262   related  to  the  Novacor
acquisition.  All financial  figures are  expressed in Canadian  dollars and are
prepared in accordance with generally accepted accounting  principles in Canada.
Financial  results for the quarter were as budgeted,  and funding is in place to
carry out our  business  plan to bring  HeartSaver  to clinical  trials and gain
expanded  use of  Novacor(R)  LVAS in North  America,  Europe,  Japan  and other
international markets.



Dr. Tofy Mussivand Chairman and Chief Scientific Officer


Roderick M. Bryden President and Chief Executive Officer


<PAGE>

World Heart Corporation
Consolidated Balance Sheets
(Canadian Dollars)

<TABLE>
<CAPTION>
                                                    March 31,         December 31,
                                                         2001                2000
                                                  (unaudited)
<S>                                               <C>                 <C>
ASSETS
Current assets
Cash and cash equivalents                         $ 36,821,098        $ 23,624,549
Short-term investments                                       -          22,696,677
Accounts receivable and other                        2,819,005           2,515,373
Prepaid expenses                                       621,227             690,122
Inventory                                            9,694,046           9,966,873
                                                  ------------        ------------
                                                    49,955,376          59,493,594
                                                  ------------        ------------

Cash pledged as collateral for capital lease           226,316             226,316
Deferred foreign exchange loss                       3,108,578             531,035
Capital assets                                       6,037,391           6,263,544
Goodwill and other intangible assets                46,208,233          49,941,394
                                                  ------------        ------------
                                                  $105,535,894        $116,455,883
                                                  ============        ============


LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued liabilities          $  6,417,693        $  6,522,676
Accrued compensation                                 1,984,784           1,792,925
Current portion of capital lease                       153,741             150,933
                                                  ------------        ------------
                                                     8,556,218           8,466,534
Future income taxes                                  2,362,536           4,828,672
Preferred shares                                    59,619,531          55,211,759
Capital lease obligation                               186,811             226,116
                                                  ------------        ------------
                                                    70,725,096          68,733,281
                                                  ------------        ------------

Shareholders' equity
Common stock
Issued and outstanding - 15,117,427 common shares   73,752,739          73,752,739
Additional paid-in capital                          36,951,336          36,951,336
Accumulated deficit                                (75,893,277)        (62,981,473)
                                                  ------------        ------------
                                                    34,810,798          47,722,602
                                                  ------------        ------------
                                                  $105,535,894        $116,455,883
                                                  ============        ============

</TABLE>

             (The accompanying notes are an integral part of these
                      consolidated financial statements.)
<PAGE>


World Heart Corporation
Consolidated Statements of Loss
(Canadian Dollars)

<TABLE>
<CAPTION>
                                                  Three months ended     Three months ended
                                                      March 31, 2001         March 31, 2000
                                                          (unaudited)            (unaudited)
<S>                                                    <C>                     <C>

Revenue (Note 2)                                       $     602,657           $          -
                                                       -------------           ------------

Cost of goods sold
Direct materials and labour                               (1,025,305)                     -
Overhead and other                                        (1,516,135)                     -
                                                       -------------           ------------
                                                          (2,541,440)                     -
                                                       -------------           ------------
Gross margin                                              (1,938,783)                     -
                                                       -------------           ------------

Expenses
Selling, general and administrative                       (2,571,905)            (1,757,540)
Research and development                                  (6,850,992)            (3,120,700)
Amortization of intangibles                               (3,733,161)                (2,000)
                                                       -------------           ------------
                                                         (13,156,058)            (4,880,240)
                                                       -------------           ------------
Loss before the undernoted                               (15,094,841)            (4,880,240)
                                                       -------------           ------------

Other income (expenses)
Foreign exchange gain                                        516,119                      -
Investment income                                            617,747                321,355
Interest expense                                          (1,624,300)                     -
                                                       -------------           ------------
Loss before income taxes                                 (15,585,275)            (4,558,885)

Recovery of future income taxes (Note 3)                   2,673,471                      -
                                                       -------------           ------------

Net loss for the period                                  (12,911,804)            (4,558,885)

Accumulated deficit, beginning of the period             (62,981,473)           (33,127,086)
                                                       -------------           ------------

Accumulated deficit, end of the period                 $ (75,893,277)          $(37,685,971)
                                                       =============           ============

Weighted average number of common shares outstanding      15,117,427             14,293,340
                                                       -------------           ------------

Basic and diluted loss per common share                $       (0.85)          $      (0.32)
                                                       =============           ============



</TABLE>
             (The accompanying notes are an integral part of these
                      consolidated financial statements.)

<PAGE>


World Heart Corporation
Consolidated Statements of Cash Flow
(Canadian Dollars)

<TABLE>
<CAPTION>
                                                            Three months ended     Three months ended
                                                                March 31, 2001         March 31, 2000
                                                                    (unaudited)            (unaudited)
<S>                                                              <C>                     <C>

CASH FLOWS FROM (USED IN)
Operating activities
Net loss for the period                                          $ (12,911,804)          $ (4,558,885)
Items not involving cash -
Amortization and depreciation                                        4,230,327                 77,875
Interest on preferred shares                                         1,624,300                      -
Recovery of future income taxes (Note 3)                            (2,673,471)                     -
Change in operating components of working capital                    1,177,324                 49,933
                                                                 -------------           ------------
                                                                    (8,553,324)            (4,431,077)
                                                                 -------------           ------------
Investing activities
Purchase of short-term investments                                           -            (20,989,507)
Redemption of short-term investments                                22,832,961             13,680,708
Payment of expenses relating to the Novacor acquisition             (1,215,262)                     -
Purchase of capital assets                                            (271,015)              (108,868)
                                                                 -------------           ------------
                                                                    21,346,684             (7,417,667)
                                                                 -------------           ------------
Financing activities
Capital lease repayments                                               (39,506)               (34,085)
Issuance of common shares through public offering                            -             15,331,875
Payment of expenses relating to the issue of common shares                   -               (129,037)
Issuance of common shares through exercise of options                        -                 71,303
Issuance of common shares through exercise of warrants                       -                 97,988
                                                                 -------------            -----------
                                                                       (39,506)            15,338,044

Effect of exchange rate changes on cash and cash equivalents           442,695                      -
                                                                 -------------            -----------

Increase in cash and cash equivalents for the period                13,196,549              3,489,300

Cash and cash equivalents beginning of the period                   23,624,549             10,969,399
                                                                 -------------            -----------

Cash and cash equivalents end of the period                      $  36,821,098           $ 14,458,699
                                                                 =============           ============

</TABLE>

             (The accompanying notes are an integral part of these
                      consolidated financial statements.)

<PAGE>

World Heart Corporation
Notes to the Consolidated Financial Statements

1 Basis of Presentation

The accompanying  unaudited interim consolidated  financial statements have been
prepared by  management  in  accordance  with  accounting  principles  generally
accepted  in Canada  (GAAP) and  pursuant  to the rules and  regulations  of the
Ontario Securities  Commission regarding interim financial  reporting.  However,
these interim  consolidated  financial statements do not conform in all respects
to the  requirements of GAAP for annual financial  statements.  They include all
assets,   liabilities,   revenues  and  expenses  of  World  Heart   Corporation
(Corporation  or WorldHeart)  and its wholly owned  subsidiary  World Heart Inc.
These unaudited condensed notes to the interim consolidated financial statements
should be read in conjunction  with the audited  financial  statements and notes
for the year ended December 31, 2000.

The  preparation  of  these  unaudited   consolidated  financial  statements  in
conformity with GAAP requires  management to make estimates and assumptions that
affect the amounts  reported in the  consolidated  financial  statements and the
accompanying  notes.  Actual  results could differ from these  estimates and the
operating  results  for  the  interim  periods  presented  are  not  necessarily
indicative  of the  results  expected  for the  full  year.  In the  opinion  of
management, these unaudited consolidated financial statements reflect all normal
and recurring  adjustments  considered necessary to state fairly the results for
the periods presented.

2 Distribution Agreement with Edwards Lifesciences

The  Corporation  has entered into a distribution  agreement  (the  Distribution
Agreement) with Edwards  Lifesciences LLC (Edwards)  whereby Edwards will be the
sole distributor, except in the United States, of the Corporation's heart assist
and heart  replacement  products for a period of five years  commencing  July 1,
2000.  As a result of the  Distribution  Agreement,  WorldHeart  is committed to
paying a minimum of US $2 million annually to Edwards in guaranteed gross margin
on sales.

3 Income Taxes

In the first  quarter of fiscal  2001,  the  Corporation  recorded a recovery of
future  income  taxes of  $2,673,471  (2000 - $nil) on a net loss before  income
taxes of $15,585,275  (2000 -  $4,558,885).  The recovery of future income taxes
relates  entirely to United  States  operations  and  reflects  the  reversal of
temporary differences and related recognition of loss carryforward amounts.


<PAGE>
4 Segmented Information

Operating  segments  are  defined as  components  of an  enterprise  about which
separate financial  information is available that is evaluated  regularly by the
Corporation's  chief  decision  maker in deciding how to allocate  resources and
assess  performance.  The  Corporation's  chief  decision maker is the Executive
Office.  The  Corporation's  reportable  segments are its commercial  operations
related to the sale of Novacor  LVAS and related  components  and  research  and
development focused mainly on development of HeartSaver. The accounting policies
of the Corporation's  operating  segments are the same as those described in the
Corporation's audited financial statements for the year ended December 31, 2000.
The  following  presents  segment  operating  results for the three months ended
March 31,  2001 and  identifiable  long-lived  assets as at March 31,  2001.  No
comparative  figures have been shown,  as the  Corporation  operated as a single
segment, research and development, in the first quarter of fiscal 2000.

<TABLE>
<CAPTION>
                                     Commercial        Research and
                                     Operations        development          Total

<S>                                 <C>               <C>              <C>
Revenue                             $  602,657        $            -   $     602,657

Cost of goods sold
Direct materials and labour          (1,025,305)                   -      (1,025,305)
Overhead and other                   (1,516,135)                   -      (1,516,135)
                                    ------------                       -------------

Gross margin                         (1,938,783)                   -      (1,938,783)
                                    ------------                       -------------

Expenses
Selling, general and administrative   1,220,521            1,351,384       2,571,905
Research and development                     -             6,850,992       6,850,992
                                    -----------       --------------   -------------
                                      1,220,521            8,202,376       9,422,897
                                    -----------       --------------   -------------
Loss before the undernoted          $(3,139,305)      $   (8,202,376)    (11,361,680)
                                    ===========       ==============
Amortization of intangibles                                               (3,733,161)
Other income (expenses), net                                                (490,434)
Recovery of future income taxes                                            2,673,471
                                                                       -------------
Net loss for the period                                                $ (12,911,804)
                                                                       ==============

Long-lived assets                   $ 20,406,140      $   31,839,484   $  52,245,624
                                    ============      ==============   =============

Additions to long-lived assets      $          -      $      271,015   $     271,015
                                    ============      ==============   =============

</TABLE>


The following  geographic area data includes  revenue based on product
shipment  destination  and  long-lived  assets based on physical  location.  All
long-lived  assets for the three-month  period ended March 31, 2000 were located
in Canada.  As at March 31, 2001, the  Corporation  has a location in Canada and
the United States:

<PAGE>
Three months ended
                                                                 March 31, 2000

                                                                      Long-lived
                                                    Revenue               assets

Canada                                                    $ -       $  5,332,154
United States                                       1,190,279         46,913,270
Netherlands                                           944,761                  -
                                                    ---------
Total                                               2,135,040       $ 52,245,624
                                                                    ============
Less: Rebate to Edwards                            (1,532,383)
                                                   ----------
                                                   $  602,657
                                                  ===========


The obligation to Edwards accrued and included as a reduction of revenue,  is as
follows:

                                                              Three months ended
                                                March 31, 2001    March 31, 2000

Gross revenue                                      $ 2,135,040           $ -
Less: Rebate to Edwards                             (1,532,383)            -
                                                   -----------
Net revenue                                        $   602,657           $ -
                                                   ===========           ===

<PAGE>

Management's  Discussion  and  Analysis of  Financial  Condition  and Results of
Operations
For the three month period ended March 31, 2001

Introduction
The following discussion is an update of the management  discussion and analysis
for the year ended  December  31,  2000 and a  discussion  of the  results  from
operations and cash flows for the three months ended March 31, 2001. World Heart
Corporation, and its wholly owned subsidiary, World Heart Inc., are collectively
referred to as "WorldHeart" or the "Corporation". In this discussion, references
to  "dollars"  or "$" or "Cdn$" are to Canadian  dollars and  references  to "US
dollars" or "US$" are to United States dollars.

Overview
WorldHeart  is  a  global  medical  device  company  currently  focused  on  the
development  and  commercialization  of  pulsatile  ventricular  assist  devices
through  operations in Oakland,  California,  USA and Ottawa,  Ontario,  Canada.
WorldHeart is currently focused on two products,  Novacor(R) LVAS (Novacor LVAS)
and HeartSaverVAD(TM)(HeartSaver). Significant progress at WorldHeart during the
quarter  includes the  commencement of long-term  pre-clinical in vivo trials of
HeartSaver and further sales of Novacor LVAS. There are no material changes from
the annual management discussion and analysis.

Financial condition
At March 31,  2001,  the  Corporation  had a working  capital  balance  of $41.4
million,  reduced from $51.0 million at December 31, 2000. The  Corporation  had
cash, cash equivalents and short-term  investments of $37.0 million at March 31,
2001 and $46.5  million at December 31, 2000.  Use of cash during the quarter is
within  the  Corporation's  budget of $36  million  for the  year.  There are no
significant  changes in the rate of cash  utilization  anticipated in subsequent
quarters. However, increased sales levels are expected to improve cash balances.
As  disclosed  in the annual  management  discussion  and  analysis,  additional
financing will be required prior to full  commercialization  of HeartSaver.  The
Corporation  has no current  arrangements  with respect to sources of additional
financing.

Results from operations
All financial  information  is prepared in accordance  with  generally  accepted
accounting principles (GAAP) in Canada and is stated in Canadian dollars.

<PAGE>

                                         Three months      As a %   Three months
                                                ended    of gross          ended
                                            March 31,     revenue      March 31,
                                                 2001                       2000
                                          (unaudited)                (unaudited)

Revenue
Gross revenue                             $ 2,135,040                    $ -
Less fee payable to Edwards                (1,532,383)                     -
                                         -------------                   ---
                                              602,657                      -
                                         ------------
Cost of goods sold
Direct materials and labour                (1,025,305)       48%           -
Overhead and other                         (1,516,135)       71%           -
                                         -------------                   ---
                                           (2,541,440)      119%           -

Gross margin                               (1,938,783)                     -
                                         -------------                   ---

Expenses
Selling, general and administrative        (2,571,905)               (1,757,540)
Research and development                   (6,850,992)               (3,120,700)
Amortization of intangibles                (3,733,161)                   (2,000)
                                         -------------              ------------
                                          (13,156,058)               (4,880,240)
                                         -------------              ------------

Other income (expenses)                      (490,434)                   321,355
                                         -------------              ------------

Loss before income taxes                  (15,585,275)               (4,558,885)
Recovery of future income taxes             2,673,471                     -
                                         -------------              ------------
Net loss for the period                  $(12,911,804)              $(4,558,885)
                                         =============              ============



Revenues
Gross  revenues  in the first  quarter  of 2001 were  $2,135,040.  There were no
revenues for the corresponding  period in the preceding fiscal year.  WorldHeart
has  entered  into  a  distribution  agreement  with  Edwards  Lifesciences  LLC
(Edwards)  whereby  Edwards will be the sole  distributor,  except in the United
States, of the Corporation's  heart assist and heart replacement  products for a
period  of five  years  that  commenced  on July 1,  2000.  As a result  of this
agreement,  WorldHeart is committed to paying a minimum of US$2 million annually
to Edwards in guaranteed  gross margin on sales. It is estimated that WorldHeart
will be committed to paying $1,532,383 to Edwards as a result of this guarantee.
The full amount of this  commitment  is  recognized at the time it becomes known
and shown as a deduction from gross revenues.


<PAGE>
Cost of goods sold and gross margins
The direct  materials  and labour  attributable  to the gross sales in the first
quarter of 2001 result in a contribution  margin of 48%. This is consistent with
the year ended December 31, 2000.
The margin,  gross  revenue less cost of goods sold,  has improved from negative
41% for the year ended  December  31, 2000 to negative  19% for the three months
ended  March  31,  2001.   There  were  no  gross  margins   generated  for  the
corresponding  period in the  preceding  fiscal year. As discussed in the annual
management  discussion and analysis,  it is anticipated  that gross margins will
continue to improve over the course of the 2001 fiscal year as the completion of
the  integration  of  operations  in Ottawa and Oakland  continues  to result in
increased efficiencies.

Consolidated expenses and other items
Selling, general and administrative expenses have increased substantially in the
first  quarter  of 2001  relative  to the first  quarter  of fiscal  2000.  This
increase is related primarily to administrative activities in supporting Novacor
LVAS including marketing, finance and human resource activities. The Corporation
will  continue  to  emphasize  marketing  and  promotional   activities  as  the
development of HeartSaver  continues and as emphasis is placed on increasing the
number of implants of Novacor LVAS devices.

Research and development  expenses for the first quarter of 2001 are 120% higher
than for the first  quarter  of 2000.  This  increase  is due  primarily  to the
increase  in  research  activities  undertaken  to further  the  development  of
HeartSaver.  In addition,  the  Corporation  commenced  its formal  pre-clinical
trials of HeartSaver.  These trials will result in significant expenditures over
the balance of the fiscal year.

Outlook
Based on the first quarter results, the Corporation expects to meet its budgeted
cash expenditures for the balance of the year.


<PAGE>

EXECUTIVE COMMITTEE

Dr. Tofy Mussivand
Chairman and
Chief Scientific Officer

Roderick M. Bryden
President and
Chief Executive Officer

Ian W. Malone
Vice-President Finance and
Chief Financial Officer

Daniela (Dani) Kennedy
Vice-President Corporate Services

Doug Hillier
Senior Vice-President

Jal Jassawalla
Senior Vice-President
Research and Development

Robert Griffin
Vice-President
Manufacturing

Linda Strauss
Vice-President
Quality and Regulatory Affairs

World Heart Corporation
Corporate Head Office: 1 Laser Street
Ottawa, Ontario, Canada K2E 7V1
Tel: (613) 226-4278 Fax: (613) 226-4744

World Heart Inc.
7799 Pardee Lane
Oakland, California, U.S.A. 94621
Tel: (510) 563-5000 Fax: (510) 563-5005

Investor Relations                        General information
enquiries:                                or media enquiries:
Corinna de Beer                           Michelle Banning
Manager, Investor Relations               Manager, Corporate Communications
Phone: (613) 226-4278, ext: 2010          Phone: (613) 226-4278, ext: 2995
Fax: (613) 226-4744                       Fax: (613) 226-4744
investors@worldheart.com                  communications@worldheart.com
________________________



<PAGE>

                                   SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.


                                        World Heart Corporation

          Date: May 29, 2001

                                        By:  /s/ Ian Malone
                                           ---------------------------------
                                           Name: Ian Malone
                                           Title:  Vice President Finance and
                                                     Chief Financial Officer